SCHEDULE: Capital International Investors Discloses 6.6% Stake in Royalty Pharma

Capital International Investors has reported a 6.6% beneficial ownership stake in Royalty Pharma PLC, holding 28,512,128 shares of common stock.

Summary

• Capital International Investors (CII) has filed an Amendment No. 1 to Schedule 13G, disclosing its beneficial ownership in Royalty Pharma PLC.
• CII beneficially owns 28,512,128 shares of Royalty Pharma PLC common stock.
• This ownership represents 6.6% of the total outstanding shares, based on 432,293,050 shares believed to be outstanding.
• CII holds sole voting power over 28,398,131 shares and sole dispositive power over 28,512,128 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership by an institutional investor, containing no inherent positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant passive investment by a major institutional asset manager, Capital International Investors, in Royalty Pharma PLC. Such filings are standard disclosures required when an entity acquires more than 5% of a company's voting class of securities, signaling institutional confidence or portfolio allocation decisions rather than active strategic involvement.

Stakeholder Impact

• Informs shareholders and the market of a significant institutional holding in Royalty Pharma PLC.
• Provides transparency regarding the ownership structure of the company.

Key Dates

Keywords

Royalty Pharma PLC, Capital International Investors, beneficial ownership, Schedule 13G, common stock, institutional investment, SEC filing, equity stake